Study Funding AgreementStudy Funding Agreement • October 17th, 2013 • Queensland
This Agreement is drafted on the basis that multiple users fund the study works. If there is only one funder or underwriter, the concept of a User Committee should be deleted as the one funder or underwriter will take on that role.
Study Funding AgreementStudy Funding Agreement • May 15th, 2003 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances) • Delaware
This Study Funding Agreement, dated as of April 23, 2003, is made by and between Targeted Genetics Corporation, a corporation organized and existing under the laws of the State of Washington, having offices located at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (“TG”), and Cystic Fibrosis Foundation Therapeutics, Inc., a not for profit corporation organized and existing under the laws of the State of Delaware, having offices located at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”) with respect to Study Protocol and involving the Compound, both as defined below.
ContractStudy Funding Agreement • March 16th, 2006 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities And Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
STUDY FUNDING AGREEMENTStudy Funding Agreement • August 11th, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • Delaware
THIS STUDY FUNDING AGREEMENT, dated as of June 17, 2003, is made by and between Hollis-Eden Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 4435 Eastgate Mall, Suite 400, San Diego, CA 92121 (“H-E”), and Cystic Fibrosis Foundation Therapeutics, Inc., a not for profit corporation organized and existing under the laws of the State of Delaware, having offices located at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”) with respect to the Study Protocol and involving the Compound, both as defined below.
ContractStudy Funding Agreement • August 7th, 2008 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Key Terms of Study Funding AgreementStudy Funding Agreement • March 19th, 2011
This document sets out the key terms of a study funding agreement. It is not exhaustive of all of the issues to be considered in such an agreement.
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Study Funding Agreement • September 19th, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows:
Exhibit 10.1 [NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND...Study Funding Agreement • October 4th, 2002 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
ContractStudy Funding Agreement • September 19th, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Study Funding Agreement • September 19th, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
The purpose of this Letter Agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned parties (the “Agreement”). By signing below, the undersigned parties agree as follows:
December 11, 2006 Chris Penland, Ph.D. Cystic Fibrosis Foundation Therapeutics, Inc.Study Funding Agreement • March 16th, 2007 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Study Funding Agreement • September 19th, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows:
ContractStudy Funding Agreement • September 19th, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
